Outlook Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 23

Employees

  • Stock Symbol
  • OTLK

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.71
  • (As of Friday Closing)

Outlook Therapeutics General Information

Description

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Contact Information

Formerly Known As
Oncobiologics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 111 South Wood Avenue
  • Unit 100
  • Iselin, NJ 08830
  • United States
+1 (609)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 111 South Wood Avenue
  • Unit 100
  • Iselin, NJ 08830
  • United States
+1 (609)

Outlook Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Outlook Therapeutics Stock Performance

As of 07-Feb-2025, Outlook Therapeutics’s stock price is $1.71. Its current market cap is $54.7M with 24.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.71 $1.73 $0.87 - $12.85 $54.7M 24.9M 2.11M -$4.06

Outlook Therapeutics Financials Summary

As of 30-Sep-2024, Outlook Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2024 30-Sep-2024 FY 2023 30-Sep-2023 FY 2022 30-Sep-2022
EV 127,021 127,021 58,545 260,394
Revenue 0 0 0 0
EBITDA (72,999) (72,999) (57,376) (64,357)
Net Income (75,367) (75,367) (58,983) (66,052)
Total Assets 28,823 28,823 32,301 28,528
Total Debt 29,738 29,738 35,555 10,958
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Outlook Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Outlook Therapeutics‘s full profile, request access.

Request a free trial

Outlook Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-501
Drug Discovery
Iselin, NJ
23 As of 2024

Waltham, MA
 

South Yarra, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Outlook Therapeutics Competitors (30)

One of Outlook Therapeutics’s 30 competitors is Apellis Pharmaceuticals, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Opthea Corporation South Yarra, Australia
Affimed Formerly VC-backed Mannheim, Germany
Henlius Formerly VC-backed Shanghai, China
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 30 competitors. Get the full list »

Outlook Therapeutics Patents

Outlook Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210230261-A1 Buffered formulations of bevacizumab for use of treating diseases Inactive 17-Apr-2018
EP-3781199-A1 Buffered formulations of bevacizumab for use of treating diseases Inactive 17-Apr-2018
AU-2019256289-A1 Buffered formulations of bevacizumab for use of treating diseases Pending 17-Apr-2018
CA-3097123-A1 Buffered formulations of bevacizumab for use of treating diseases Pending 17-Apr-2018
EP-3411719-A1 Methods for identifying and analyzing amino acid sequences of proteins Inactive 04-Feb-2016 G01N33/6818
To view Outlook Therapeutics’s complete patent history, request access »

Outlook Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Outlook Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Outlook Therapeutics‘s full profile, request access.

Request a free trial

Outlook Therapeutics Investments (1)

Outlook Therapeutics’s most recent deal was a Joint Venture with Joint Venture (Outlook Therapeutics / Syntone Technologies) for . The deal was made on 04-Feb-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Outlook Therapeutics / Syntone Technologies) 04-Feb-2021 Joint Venture Pharmaceuticals
To view Outlook Therapeutics’s complete investments history, request access »

Outlook Therapeutics ESG

Risk Overview

Risk Rating

Updated March, 01, 2024

33.58 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Outlook Therapeutics’s complete esg history, request access »

Outlook Therapeutics FAQs

  • When was Outlook Therapeutics founded?

    Outlook Therapeutics was founded in 2010.

  • Where is Outlook Therapeutics headquartered?

    Outlook Therapeutics is headquartered in Iselin, NJ.

  • What is the size of Outlook Therapeutics?

    Outlook Therapeutics has 23 total employees.

  • What industry is Outlook Therapeutics in?

    Outlook Therapeutics’s primary industry is Drug Discovery.

  • Is Outlook Therapeutics a private or public company?

    Outlook Therapeutics is a Public company.

  • What is Outlook Therapeutics’s stock symbol?

    The ticker symbol for Outlook Therapeutics is OTLK.

  • What is the current stock price of Outlook Therapeutics?

    As of 07-Feb-2025 the stock price of Outlook Therapeutics is $1.71.

  • What is the current market cap of Outlook Therapeutics?

    The current market capitalization of Outlook Therapeutics is $54.7M.

  • Who are Outlook Therapeutics’s competitors?

    Apellis Pharmaceuticals, Opthea, Affimed, Henlius, and Immunocore Holdings are some of the 30 competitors of Outlook Therapeutics.

  • What is Outlook Therapeutics’s annual earnings per share (EPS)?

    Outlook Therapeutics’s EPS for 12 months was -$4.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »